Dublin, Ireland-based Covidien plc COV announced on Tuesday morning that it beat consensus Wall Street estimates.
Covidien plc reported that its 1st quarter net income rose 15.6% to $427 million, or 86 cents per share, up from $412 million, or 82 cents per share, a year earlier.
Excluding special items, the company's earnings came in at 95 cents per share.
Covidien plc reported revenue of $2.77 billion, up 5% from $2.64 billion a year earlier.
According to a survey of analysts by Thomson Reuters, the average Wall Street estimate called for earnings of 81 cents per share, on revenue of $2.73 billion.
Covidien plc (COV) closed the previous trading day at $47.47 per share. Analysts covering the company's stock give it a consensus price target of $52.83 per share.
Covidien plc is a leading global healthcare products company that creates medical solutions for better patient outcomes and delivers value through clinical leadership and excellence.
The company manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies.
Read more from Benzinga's Company news.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in